MeSH term
Frequency | Condition_Probility | Adult | 12 | 0.0 |
Aged | 18 | 0.0 |
Female | 23 | 0.0 |
Humans | 55 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Male | 21 | 0.0 |
Middle Aged | 19 | 0.0 |
Prognosis | 2 | 0.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Rats | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 15 | 0.0 |
Research Support, Non-U.S. Gov't | 35 | 0.0 |
3T3 Cells | 3 | 0.0 |
Animals | 18 | 0.0 |
Cell Adhesion | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Cell Line | 6 | 0.0 |
Cell Movement | 3 | 0.0 |
Fibronectins/metabolism | 2 | 1.0 |
Mice | 8 | 0.0 |
Neoplasm Invasiveness | 6 | 0.0 |
Stromelysin 1/metabolism | 2 | 13.0 |
*Alleles | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
Genotype | 12 | 0.0 |
Polymorphism, Genetic | 5 | 0.0 |
Prospective Studies | 3 | 0.0 |
Stromelysin 1/*genetics | 10 | 58.0 |
Alleles | 7 | 0.0 |
Comparative Study | 8 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Risk Factors | 5 | 0.0 |
Gelatinase B/genetics/metabolism | 2 | 16.0 |
Cell Line, Tumor | 3 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Neoplasm Invasiveness/genetics | 2 | 4.0 |
Catalytic Domain | 2 | 0.0 |
Models, Molecular | 2 | 0.0 |
Base Sequence | 3 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Genetics, Population | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
Molecular Sequence Data | 4 | 0.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Stromelysin 1/*genetics/metabolism | 3 | 75.0 |
Cells, Cultured | 5 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 2 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Models, Biological | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Time Factors | 2 | 0.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Gene Frequency | 3 | 0.0 |
Genetic Predisposition to Disease | 4 | 0.0 |
Interstitial Collagenase/genetics | 2 | 18.0 |
Odds Ratio | 3 | 0.0 |
Polymorphism, Genetic/genetics | 3 | 0.0 |
Risk | 2 | 0.0 |
Gelatinase B/metabolism | 2 | 3.0 |
Analysis of Variance | 2 | 0.0 |
Blotting, Western | 3 | 0.0 |
Matrix Metalloproteinases/*biosynthesis | 2 | 18.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Interstitial Collagenase/*genetics | 2 | 18.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Amino Acid Sequence | 2 | 0.0 |
Protein Binding | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Culture Media, Conditioned/pharmacology | 2 | 1.0 |
Stromelysin 1/genetics | 2 | 11.0 |
Tumor Cells, Cultured | 4 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Finland | 2 | 0.0 |
Gelatinase A | 3 | 4.0 |
Gelatinase B | 3 | 3.0 |
Interstitial Collagenase | 4 | 9.0 |
Metalloendopeptidases/*metabolism | 3 | 3.0 |
Culture Media, Conditioned | 2 | 0.0 |
Lymphatic Metastasis | 2 | 0.0 |
English Abstract | 3 | 0.0 |
Pedigree | 2 | 0.0 |
Extracellular Matrix/*enzymology | 2 | 15.0 |
Blotting, Northern | 3 | 0.0 |
*Extracellular Matrix Proteins | 2 | 1.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Tissue Inhibitor of Metalloproteinases | 4 | 6.0 |
Adolescent | 2 | 0.0 |
Stromelysin 1 | 5 | 13.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Matrix Metalloproteinases/biosynthesis/genetics | 2 | 33.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Collagenases/*metabolism | 2 | 7.0 |
In Situ Hybridization | 3 | 0.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Severity of Illness Index | 3 | 0.0 |
